KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Operating Leases (2019 - 2025)

Historic Operating Leases for Neogenomics (NEO) over the last 8 years, with Q3 2025 value amounting to $64.3 million.

  • Neogenomics' Operating Leases rose 346.3% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 346.3%. This contributed to the annual value of $60.8 million for FY2024, which is 1035.79% down from last year.
  • As of Q3 2025, Neogenomics' Operating Leases stood at $64.3 million, which was up 346.3% from $66.6 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Operating Leases peaked at $79.3 million during Q3 2021, and registered a low of $51.5 million during Q1 2021.
  • Over the past 5 years, Neogenomics' median Operating Leases value was $65.5 million (recorded in 2023), while the average stood at $65.7 million.
  • In the last 5 years, Neogenomics' Operating Leases soared by 7091.21% in 2021 and then plummeted by 1201.06% in 2023.
  • Quarter analysis of 5 years shows Neogenomics' Operating Leases stood at $72.3 million in 2021, then fell by 4.62% to $69.0 million in 2022, then dropped by 1.57% to $67.9 million in 2023, then dropped by 10.36% to $60.8 million in 2024, then grew by 5.73% to $64.3 million in 2025.
  • Its last three reported values are $64.3 million in Q3 2025, $66.6 million for Q2 2025, and $59.9 million during Q1 2025.